Your browser is no longer supported. Please, upgrade your browser.
Settings
SYRS Syros Pharmaceuticals, Inc. daily Stock Chart
SYRS [NASD]
Syros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.11 Insider Own13.15% Shs Outstand31.94M Perf Week-4.14%
Market Cap377.21M Forward P/E- EPS next Y-2.54 Insider Trans- Shs Float28.92M Perf Month-7.59%
Income-57.00M PEG- EPS next Q-0.50 Inst Own72.00% Short Float5.69% Perf Quarter-5.97%
Sales0.40M P/S943.03 EPS this Y47.50% Inst Trans0.22% Short Ratio8.18 Perf Half Y9.35%
Book/sh3.44 P/B3.43 EPS next Y-21.50% ROA-57.80% Target Price21.33 Perf Year-35.64%
Cash/sh3.81 P/C3.10 EPS next 5Y- ROE-67.10% 52W Range6.30 - 24.38 Perf YTD21.38%
Dividend- P/FCF- EPS past 5Y- ROI-83.70% 52W High-51.55% Beta-
Dividend %- Quick Ratio5.80 Sales past 5Y- Gross Margin- 52W Low87.46% ATR0.61
Employees56 Current Ratio5.80 Sales Q/Q-63.60% Oper. Margin- RSI (14)48.74 Volatility5.41% 5.63%
OptionableYes Debt/Eq0.00 EPS Q/Q3.10% Profit Margin- Rel Volume0.55 Prev Close12.07
ShortableYes LT Debt/Eq0.00 EarningsAug 09 BMO Payout- Avg Volume201.19K Price11.81
Recom2.00 SMA202.95% SMA50-2.91% SMA200-3.39% Volume110,294 Change-2.15%
Mar-13-18Reiterated Wedbush Outperform $11 → $13
Oct-31-17Resumed Piper Jaffray Overweight $30
Oct-23-17Initiated ROTH Capital Neutral $15
Aug-10-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-10-18 08:01AM  Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018 Business Wire
Jun-15-18 02:39PM  2 Stable and 2 Speculative Biotech Stocks to Buy InvestorPlace
Jun-14-18 04:01PM  Syros Announces Appointment of Michael W. Bonney to Its Board of Directors Business Wire
May-30-18 08:01AM  Syros to Present at Upcoming Investor Conferences Business Wire
May-21-18 08:20AM  Report: Exploring Fundamental Drivers Behind Syros Pharmaceuticals, J & J Snack Foods, Wright Medical Group N.V, HCI Group, Tennant, and Ebix New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
May-16-18 05:01PM  Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting Business Wire
May-11-18 03:43PM  Edited Transcript of SYRS earnings conference call or presentation 10-May-18 12:30pm GMT Thomson Reuters StreetEvents +8.33%
May-10-18 07:30AM  Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones Business Wire -5.34%
May-03-18 08:01AM  Syros to Report First Quarter 2018 Financial Results on Thursday, May 10, 2018 Business Wire -5.36%
Apr-16-18 08:01AM  Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer Business Wire
Mar-26-18 08:30AM  Report: Developing Opportunities within AllianceBernstein Holding, Deutsche Bank Aktiengesellschaft, Syros Pharmaceuticals, Ply Gem, Ensco plc, and Berkshire Hills Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-14-18 04:30PM  Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting Business Wire
Mar-12-18 07:15AM  Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones Business Wire
07:00AM  Syros Announces Appointment of Joseph J. Ferra as Chief Financial Officer Business Wire
Mar-05-18 08:32AM  Syros to Present at Upcoming Investor Conferences Business Wire
Feb-08-18 08:01AM  Syros to Present at Leerink Partners 7th Annual Global Healthcare Conference Business Wire -6.59%
Feb-07-18 04:01PM  Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Business Wire +6.30%
Jan-30-18 08:59PM  Syros Announces Pricing of $40 Million Public Offering of Common Stock Business Wire
04:01PM  Syros Announces Proposed Offering of Common Stock Business Wire
Jan-24-18 07:40AM  New Research Coverage Highlights Oracle, General Dynamics, Agile Therapeutics, Fidelity Southern, Syros Pharmaceuticals, and MSA Safety Incorporated Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-22-18 08:01AM  Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RAR Agonist Business Wire
Jan-08-18 08:01AM  Syros Announces 2018 Strategic Priorities and Expected Milestones Business Wire
08:00AM  Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms Business Wire
Jan-04-18 08:01AM  Syros to Present at 36th Annual J.P. Morgan Healthcare Conference Business Wire +5.35%
Jan-02-18 08:01AM  Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RAR Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients Business Wire
Dec-13-17 08:57AM  Syros Pharmaceuticals (SYRS) in Focus: Stock Moves 12.7% Higher Zacks
Dec-11-17 02:30PM  5 Keys To Understanding Syros Pharma's ASH Presentation Benzinga -31.69%
01:12PM  Here's Why Syros Pharmaceuticals Got Crushed Today Motley Fool
12:13PM  Syros Pharmaceuticals Plummets in Premarket Trading Monday GuruFocus.com
09:28AM  Should You Be Content With Syros Pharmaceuticals Incs (SYRS) 71.5% Earnings Growth? Simply Wall St.
Dec-10-17 09:01AM  Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach Business Wire
09:01AM  Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Business Wire
Dec-07-17 08:01AM  Syros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium Business Wire
Dec-01-17 07:12AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : December 1, 2017 Capital Cube
Nov-27-17 07:50AM  Blog Exposure - Exelixis Announces Phase-3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma ACCESSWIRE
Nov-21-17 08:01AM  Syros to Present at 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-14-17 07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
Nov-13-17 04:01PM  Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium Business Wire
08:01AM  Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer Business Wire
Nov-08-17 08:01AM  Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones Business Wire -5.27%
Nov-02-17 01:08PM  Syros Pharmaceuticals, Inc. Value Analysis (NASDAQ:SYRS) : November 2, 2017 Capital Cube -16.79%
Nov-01-17 09:01AM  Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH Annual Meeting Business Wire -11.69%
08:14AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : November 1, 2017 Capital Cube
Oct-30-17 08:01AM  Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference Business Wire +6.55%
Oct-26-17 08:01AM  Syros Drug Discovery Research in Immuno-Oncology Highlighted in Oral Presentation at American College of Surgeons Clinical Congress Business Wire -5.15%
Oct-20-17 04:01PM  Syros Announces Oral Presentation Highlighting Its Drug Discovery Research in Immuno-Oncology at American College of Surgeons Clinical Congress Business Wire
Oct-16-17 04:01PM  Syros to Present New Preclinical PK and PD Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference Business Wire
Oct-05-17 08:01AM  Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML Business Wire
Sep-29-17 08:01AM  Syros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AML Business Wire
Sep-11-17 07:01AM  Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RAR Agonist, in Genomically Defined AML and MDS Patients Business Wire -6.52%
Sep-05-17 08:01AM  Syros Pharmaceuticals to Present at Morgan Stanley 15th Annual Global Healthcare Conference Business Wire
Sep-01-17 11:40AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : September 1, 2017 Capital Cube
Aug-31-17 08:01AM  Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress Business Wire
Aug-21-17 09:20AM  Syros Pharma Wins Orphan Designation From FDA 24/7 Wall St.
08:01AM  Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML Business Wire
Aug-10-17 08:01AM  Syros Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference Business Wire -7.84%
Aug-09-17 04:05PM  Syros Reports Second Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones Business Wire
Jul-21-17 08:01AM  Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients Business Wire +5.29%
Jun-23-17 08:01AM  Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RAR Agonist, in Genomically Defined AML and MDS Patients Business Wire
Jun-19-17 08:01AM  Syros Presents Discovery of Key Genes Controlling the Autoimmune Response in Lupus in Late-Breaking Oral Presentation at FOCIS Meeting Business Wire +5.63%
Jun-15-17 03:25PM  ETFs with exposure to Syros Pharmaceuticals, Inc. : June 15, 2017 Capital Cube
Jun-13-17 04:01PM  Syros to Participate in JMP Securities Life Sciences Conference Business Wire
08:24AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : June 13, 2017 Capital Cube
Jun-12-17 08:01AM  Syros Appoints Srinivas Akkaraju to Its Board of Directors Business Wire +9.86%
May-29-17 08:20AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : May 29, 2017 Capital Cube
May-18-17 08:01AM  Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients Business Wire
May-15-17 04:31PM  Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones Business Wire
08:01AM  Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors Business Wire
May-11-17 07:36PM  Syros Pharmaceuticals, Inc. Value Analysis (NASDAQ:SYRS) : May 11, 2017 Capital Cube
May-09-17 08:52AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : May 9, 2017 Capital Cube
May-08-17 04:01PM  Syros Announces Late-Breaking Oral Presentation on its Research Identifying Key Genes that Control the Auto-immune Response in Lupus at FOCIS Meeting Business Wire
08:01AM  Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RAR Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference Business Wire
May-04-17 04:01PM  Syros Reveals Discovery of Novel Drug Targets for Triple Negative Breast Cancer Business Wire
May-01-17 08:01AM  Syros Participates in International Symposium to Support MDS Foundations Efforts to Raise Awareness of Novel Therapies in Development for MDS Business Wire
Apr-27-17 08:01AM  Syros to Present on Its Pioneering Approach to Identify Novel Drug Targets Linked to Genomically Defined Subsets of Patients at IMPAKT Breast Cancer Conference Business Wire
Apr-26-17 04:05PM  Syros Closes $35 Million Private Financing Business Wire
Apr-21-17 08:01AM  Syros Announces $35 Million Private Placement Business Wire
Apr-18-17 08:01AM  Syros to Present on SY-1425, Its First-in-Class Selective RAR Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference Business Wire
Apr-10-17 08:01AM  Syros Announces FDA Acceptance of IND to Advance SY-1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors Business Wire
Apr-04-17 08:01AM  Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RAR Agonist, for Genomically Defined AML and MDS Patients Business Wire
08:01AM  Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RAR Agonist, for Genomically Defined AML and MDS Patients
Apr-03-17 08:01AM  Syros Presents New Preclinical Data at AACR Showing Anti-Tumor Activity of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Multiple Difficult-to-Treat Solid Tumors Business Wire
Mar-31-17 08:31AM  Can Syros Pharmaceuticals (SYRS) Run Higher on Strong Earnings Estimate Revisions? Zacks
08:31AM  Can Syros Pharmaceuticals (SYRS) Run Higher on Strong Earnings Estimate Revisions?
Mar-24-17 06:33AM  Can The Uptrend Continue for Syros Pharmaceuticals (SYRS)? Zacks
06:33AM  Can The Uptrend Continue for Syros Pharmaceuticals (SYRS)?
Mar-23-17 01:04PM  SYROS PHARMACEUTICALS, INC. Financials
08:51AM  Syros Pharmaceuticals Stock: 3 Reasons Why SYRS Is a Top Choice for Momentum Investors Zacks
08:51AM  Syros Pharmaceuticals Stock: 3 Reasons Why SYRS Is a Top Choice for Momentum Investors
Mar-21-17 09:55AM  Syros Pharmaceuticals, Inc. :SYRS-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017 Capital Cube -8.67%
09:55AM  Syros Pharmaceuticals, Inc. :SYRS-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
Mar-20-17 08:01AM  Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones Business Wire
07:02AM  SYROS PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-01-17 04:31PM  Syros to Present New Data on Lead Drug Candidates, SY-1425 and SY-1365, and CDK12/13 Inhibitor Program at Upcoming AACR Annual Meeting Business Wire
08:01AM  Syros Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Feb-27-17 08:01AM  Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference Business Wire
Feb-21-17 08:01AM  Syros Drug Discovery Research in Immuno-Oncology Highlighted at UCSD Moores Cancer Center Symposium Business Wire
Feb-09-17 04:01PM  Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer Business Wire
Feb-07-17 08:01AM  Syros Pharmaceuticals to Present at 2017 BIO CEO & Investor Conference Business Wire
Jan-30-17 08:39AM  SYROS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.